Fig. 5: Specificity of NAPs for LPS-inflamed lungs versus oedematous lungs and SPECT imaging of NAPs in LPS-inflamed lungs.

a, Three-dimensional reconstructions of chest CT data for naive mouse lungs and lungs with CPO. White/yellow indicates lower attenuation, corresponding to airspace in healthy lungs. Red/dark background indicates higher attenuation, corresponding to fluid in the lungs. b, Quantification of CT attenuation in naive (blue) and oedematous (yellow) lungs, averaged across axial slices (individual slice values in Supplementary Fig. 32). c, Biodistributions of 200 nm lysozyme–dextran NGs in naive mice, mice treated with i.v.-LPS and mice subject to CPO (n = 4 animals). Naïve and i.v.-LPS data are identical to that presented in Supplementary Fig. 13, upper right panel. Inset: ratio of NP uptake in the lungs to NP uptake in the liver. For comparison of CPO and i.v.-LPS values, *P < 1 × 10⁻¹⁰ for main panel and P = 0.005 for inset. d, Co-registered CT (greyscale) and SPECT (red/yellow) images indicating ¹¹¹In-labelled lysozyme–dextran NG uptake in a naive and an i.v.-LPS-affected mouse. White/yellow indicates more nanogel uptake. Red/dark background indicates less lysozyme–dextran NG uptake. Statistical significance in c is derived from two-way ANOVA with Tukey’s multiple-comparisons test. All error bars indicate mean ± s.e.m.